

Carbiotix receives first animal related LinkGut service order

Carbiotix (publ) ("Carbiotix" or the "Company") announces today that the Company's first ever animal-related LinkGut service order from a leading company developing microbiome intervention solutions for different human and animal applications. This test order relates to samples taken from canines and is valued at 32,000 SEK. This is the first time that Carbiotix has offered its LinkGut microbiome diagnostic service for animal related applications. This development increases the potential customer base for the LinkGut service, now including both human and animal applications.

Erik Deaner, CEO of Carbiotix, comments:

"I am very pleased to announce that Carbiotix has ventured into the animal microbiome diagnostics market with the first LinkGut service order for an animal application. Although the value of this first test order is only 32,000 SEK, it is symbolic and demonstrates the viability and appeal of the LinkGut service for animal related applications. Even though animals are not our core business, the flexibility of our LinkGut service offer makes it attractive for areas other than human applications. This includes animals trained for special purposes, such as K-9s, companion animals such as dogs and cats, animals involved in husbandry activities, as well as wild animals being researched.

As with human applications, customers studying animals are looking for a microbiome service provider that can provide value with regards to cost, flexibility and reliability. We will continue to market our leadership position across all three of these areas and continue to explore new opportunities in the over 2 Billion Euro market for microbiome sequencing services [\(1\)](#).

This development also has the potential to assist Carbiotix to begin selling its prebiotic modulators for animal food related applications like pet food, as well as investigating potential upcycling opportunities with pet food and animal husbandry companies through the NutraCycle service.

This is information that Carbiotix AB is obliged to make public according to the EU Market Abuse Regulation (MAR). The information was made publicly available by the Company's contact person set out below on 12 March 2024.

Forward-looking statements

This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios as described in this press release.

For further information:

Carbiotix AB
Erik Deaner, CEO
Tel: +46 (0)738 67 30 85
E-mail: erik.deaner@carbiotix.com

Carbiotix AB (CRBX) (www.carbiotix.com) is an award-winning biotechnology company pioneering microbiome healthcare through a portfolio of prebiotic modulators and diagnostic testing services.